FUM is widely reported around 30.00p – 30.60p. quoted over 2,000% by investment trackers.23 Apr 2026 12:45
Analyst targets for Futura Medical PLC (AIM: FUM) indicate a significant potential upside, with a consensus price target around 30.00p, suggesting a high-growth outlook based on Eroxon (MED3000) commercialization. Analysts anticipate a shift towards profitability as the company launches in the US market.
Consensus Price Target: The 12-month analyst consensus target price for FUM is widely reported around 30.00p – 30.60p.
Implied Growth: With the share price recently trading near 1.05p – 1.33p, this consensus target implies a significant potential upside, often quoted over 2,000% by investment trackers.
Analyst Outlook: The sentiment is generally positive, driven by the rollout of Eroxon in the US and the expected cash runway provided by partner agreements, according to reports from Trinity Delta and other market observers.
Profitability Forecast: Analysts expect the company to move from losses to profitability, with some estimates indicating a breakeven point and potential profit .